Tarloff J B, Goldstein R S, Hook J B
Department of Investigative Toxicology, Smith Kline & French Laboratories, King of Prussia, PA 19406-0939.
Toxicology. 1989 Jun 1;56(2):167-77. doi: 10.1016/0300-483x(89)90131-5.
Strain differences in susceptibility of rats to acetaminophen (APAP)-induced nephrotoxicity have been previously reported. Young adult male Fischer-344 (F-344) rats are susceptible whereas weight-matched Sprague-Dawley (SD) rats are not susceptible to APAP nephrotoxicity. The present study was designed to evaluate the role of pharmacokinetics in strain-dependent APAP nephrotoxicity. Age-matched (2-month-old) male F-344 and SD rats received 250-750 mg APAP/kg, i.v., or 0-1000 mg APAP/kg, i.p. Pharmacokinetic variables were evaluated following i.v. APAP and 24 h urinary excretion of APAP and major metabolites was determined following both i.v. and i.p. administration of APAP. Following i.p. administration, nephrotoxicity was observed only in F-344 rats following 1000 mg APAP/kg; SD rats were not susceptible to APAP-induced nephrotoxicity. In contrast, nephrotoxicity did not occur in either F-344 or SD rats administered APAP i.v. Pharmacokinetic variables (volume of distribution, apparent systemic clearance, and apparent terminal half-life) of APAP were similar in F-344 and SD rats. No striking differences in the pattern of specific urinary metabolites were observed between F-344 and SD rats treated with i.p. or i.v. APAP. Thus, strain differences in APAP-induced nephrotoxicity do not appear to be due to differences in pharmacokinetics or major pathways of APAP metabolism.
先前已有报道大鼠对乙酰氨基酚(APAP)诱导的肾毒性的易感性存在品系差异。年轻成年雄性Fischer-344(F-344)大鼠易感,而体重匹配的Sprague-Dawley(SD)大鼠对APAP肾毒性不易感。本研究旨在评估药代动力学在品系依赖性APAP肾毒性中的作用。年龄匹配(2个月大)的雄性F-344和SD大鼠静脉注射250 - 750 mg APAP/kg,或腹腔注射0 - 1000 mg APAP/kg。静脉注射APAP后评估药代动力学变量,并在静脉注射和腹腔注射APAP后测定APAP及其主要代谢产物的24小时尿排泄量。腹腔注射后,仅在给予1000 mg APAP/kg的F-344大鼠中观察到肾毒性;SD大鼠对APAP诱导的肾毒性不易感。相比之下,静脉注射APAP的F-344或SD大鼠均未发生肾毒性。APAP的药代动力学变量(分布容积、表观全身清除率和表观终末半衰期)在F-344和SD大鼠中相似。在腹腔注射或静脉注射APAP处理的F-344和SD大鼠之间,未观察到特定尿代谢产物模式的显著差异。因此,APAP诱导的肾毒性的品系差异似乎不是由于药代动力学或APAP代谢主要途径的差异所致。